Yuki Fujimoto Author
Subjects of specialization
Affiliation
cancer, cancer oncology, Carcinogenesis
Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan
Dr. Yuki Fujimoto is working as scientist and professor at Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan. The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy
Case Report Open Access
Author(s): Yoko Ishige, Ryo Kato, Shohei Shinomiya*, Yutaka Takahara, Yuki Fujimoto, Taku Oikawa and Shiro Mizuno (Japan)
The frequency of immune checkpoint inhibitor (ICI) use in lung cancer chemotherapy has increased and has been associated with an increasing frequency of Immune-Related Adverse Events (IRAEs). Although IRAEs mainly include interstitial pneumonia, colitis, thyroid dysfunction and type 1 diabetes, other adverse events have been reported. Case: A 46-year old man was admitted to our hospital with chest pain. Computed Tomography (CT) of the chest showed a mediastinal nodule and osteolysis at the Th8 level. Lung adenocarcinoma was diagnosed from transbronchial biopsy during bronchoscopy, and expression of programmed death-ligand 1 was 95%, so chemotherapy with pembrolizumab monotherapy was started. After pembrolizumab administration, serum eosinophil count increased, and systemic fatigue appea... view moreĀ»